SCHEMBL6285671

SCHEMBL6285671

CC(C)c1cnc(NC(=O)Nc2cccnc2)s1

nearest known ligand 0.76

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK2 P24941 7/20 0.76
CCNE1 P24864 6/20 0.76
CDK5 Q00535 6/20 0.76
POLB P06746 1/20 0.54
P2RX4 Q99571 1/20 0.54
RAB9A P51151 7/20 0.53
NPC1 O15118 6/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
ALDH1A1 P00352 3/20 0.52
CCNT1 O60563 1/20 0.52
CDK1 P06493 1/20 0.52
CDK4 P11802 1/20 0.52
CCNB1 P14635 1/20 0.52
CCNA2 P20248 1/20 0.52
CCND1 P24385 1/20 0.52
CDK7 P50613 1/20 0.52
CDK9 P50750 1/20 0.52
CCNH P51946 1/20 0.52
MNAT1 P51948 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284074 0.87 CDK2 (1.00) CDK2CCNE1CDK5RAB9ANPC1
SCHEMBL6283519 0.85 CDK2 (0.78) CDK2CCNE1CDK5RAB9ANPC1
SCHEMBL6285653 0.83 RAB9A (0.63) CDK2CCNE1CDK5RAB9ANPC1
SCHEMBL6279171 0.81 CDK2 (0.74) CDK2CCNE1CDK5POLBMEN1
SCHEMBL6282898 0.81 CDK2 (0.74) CDK2CCNE1CDK5RAB9ANPC1
SCHEMBL6287941 0.81 CDK2 (0.74) CDK2CCNE1CDK5POLBALDH1A1
SCHEMBL6286739 0.81 ATG4B (0.64) CDK2CCNE1CDK5POLBMEN1
SCHEMBL6279150 0.80 TSHR (0.55) CDK2CCNE1CDK5POLBP2RX4
SCHEMBL6282655 0.80 CDK2 (0.78) CDK2CCNE1CDK5POLBRAB9A
SCHEMBL6285271 0.80 CDK2 (0.78) CDK2CCNE1CDK5RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US claimed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US claimed
US-6863647-B2 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN S.P.A. (IT) 2005-03-08 US disclosed
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PEVARELLO PAOLO (IT) 2004-08-12 US disclosed
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents PHARMACIA & UPJOHN SPA (IT) 2003-10-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030187040-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885
US-20040157827-A1 2-Ureido-thiazole derivatives, process for their preparation, and their use as antitumor agents UCK2, ULK3, CDK2 CDK2 3/4885CCNE1 83/4885CDK5 129/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.